Filing Flows › Biocryst Pharmaceuticals (BCRX) › Capital expenditures
Biocryst Pharmaceuticals (BCRX) capital expenditures by quarter
Biocryst Pharmaceuticals' capital expenditures were $233K in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 5 quarters it ranged from $179K (Q2 2025) to $1.3M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $233K | +11% | -83% |
| Q2 2026 | $209K | -74% | +17% |
| Q4 2025 | $802K | -40% | — |
| Q3 2025 | $1.3M | +651% | — |
| Q2 2025 | $179K | — | — |
Q3 2026 at a glance
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biocryst Pharmaceuticals' capital expenditures?
Biocryst Pharmaceuticals' capital expenditures were $233K in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Biocryst Pharmaceuticals' capital expenditures changed?
Over the last 5 quarters it ranged from $179K (Q2 2025) to $1.3M (Q3 2025).
Q3 2026 results → · How Biocryst Pharmaceuticals makes money →